CGA M-21

Guideline for Determining Pharmacovigilance Reporting Requirements in North America

Compressed Gas Association , 10/06/2022

Publisher: CGA

File Format: PDF

$13.00$27.00


This publication provides guidance for pharmacovigilance reporting to FDA and Health Canada. This guidance is intended to aid United States and Canadian companies that market common medical gases (i.e., oxygen, nitrogen, medical air, carbon dioxide, nitrous oxide, helium, and carbon monoxide and medically appropriate mixtures thereof) in setting up a pharmacovigilance reporting system that satisfies local and regional regulatory requirements, bearing in mind any global requirements when applicable.

This publication does not address reporting requirements for gases or medical gas equipment classified as medical devices (materiovigilance).

CGA continues to work with the FDA and Health Canada on pharmacovigilance requirements for common medical gases.

CGA M-21 History

CGA M-21

CGA M-21

$13.00 $27.00

CGA M-21

CGA M-21

$13.00 $27.00

More CGA Standards PDF

CIE x050-OP043

CIE x050-OP043

$19.00 $38.00

CIE x050-PO004

CIE x050-PO004

$19.00 $38.00

CIE x050-PO071

CIE x050-PO071

$19.00 $38.00

CIE x050-OP031

CIE x050-OP031

$19.00 $38.00